Network graphs of eligible comparisons for efficacy.
2021
Bild
Zugriff:
The size of the circles is proportional to sample size, and the width of lines is proportional to the number of trials. Interventions: acarbose (ACR), alfacalcidol (ALF), anastrozole (ANZ), clomiphene citrate (CC), exenatide (EXN), folic acid (FA), flutamide (FLT) pure follicle-stimulating hormone (FSH), human menopausal gonadotropins (HMG), inositol (INS), letrozole (LET), liraglutide (LIR), metformin (MET), medroxyprogesterone acetate (MPA), N-acetyl cysteine (NAC), orlistat (ORL), pioglitazone (PGZ), placebo (PLC), rosiglitazone (RGZ), sibutramine (SBT), simvastatin (SMV), and troglitazone (TGZ). Acarbose+clomiphene citrate (ACR+CC), alfacalcidiol+metformin (ALF+MET), atorvastatin+metformin (ATR+MET), bromocriptine+clomiphene citrate (BRM+CC), bromocriptine+metformin (BRM+MET), clomiphene citrate+dexamethasone (CC+DEX), clomiphene citrate+ketoconazole (CC+KTZ), clomiphene citrate+l-carnitine (CC+LC), clomiphene citrate+l-carnitine+metformin (CC+LC+MET), clomiphene citrate+metformin (CC+MET), clomiphene citrate+N-acetylcysteine (CC+NAC), clomiphene citrate+rosiglitazone (CC+RGZ), chlormadinone acetate+ethinylestradiol (CHA+EE), cyproterone acetate+ethinylestradiol (CPA+EE), cyproterone acetate+ethinylestradiol+metformin (CPA+EE+MET), cyproterone acetate+ethinylestradiol+metformin+orlistat (CPA+EE+MET+ORL), cyproterone acetate+ethinylestradiol+orlistat (CPA+EE+ORL), cyproterone acetate+ethinylestradiol+spironolactone (CPA+EE+SPR), dexamethasone+metformin (DEX+MET), desogestrel+ethinylestradiol (DGT+EE), drospirenone+ethinylestradiol (DPN+EE), drospirenone+ethinylestradiol+metformin (DPN+EE+MET), ethinylestradiol+flutamide+levonorgestrel (EE+FLT+LVT), ethinylestradiol+gestodene (EE+GTN), ethinylestradiol+metformin+norgestimate (EE+MET+NRG), ethinylestradiol+norgestimate (EE+NRG), folic acid+inositol (FA+INS), flutamide+metformin (FLT+MET), human menopausal gonadotropins+ leuprolide (HMG+LPR), inositol+monacolin k (INS+MNK), letrozole+metformin (LET+MET), metformin+rosuvastatin (MET+RSV), and ...
Titel: |
Network graphs of eligible comparisons for efficacy.
|
---|---|
Autor/in / Beteiligte Person: | Mohamed Abdel-Maboud (9744170) ; Amr Menshawy (9744173) ; Elfatih A. Hasabo (7377698) ; Mohamed Ibrahim Abdelraoof (11154319) ; Mohamed Alshandidy (9744182) ; Muhammad Eid (9744185) ; Esraa Menshawy (9744176) ; Oumaima Outani (9976109) ; Ahmed Menshawy (11154322) |
Link: | |
Veröffentlichung: | 2021 |
Medientyp: | Bild |
DOI: | 10.1371/journal.pone.0254412.g002 |
Schlagwort: |
|
Sonstiges: |
|